Section Arrow
PHVS.NASDAQ
- Pharvaris NV
Quotes are at least 15-min delayed:2026/08/04 17:36 EDT
After Hours
Last
 34.54
+0.67 (+1.98%)
Bid
30.4
Ask
36.15
High 34.54 
Low 33.76 
Volume 2.11K 
Regular Hours (Closed)
Last
 33.87
+1.62 (+5.02%)
Day High 
33.87 
Prev. Close
32.25 
1-M High
36.6 
Volume 
250.59K 
Bid
30.4
Ask
36.15
Day Low
32.59 
Open
32.75 
1-M Low
31.51 
Market Cap 
2.25B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 33.52 
20-SMA 34.18 
50-SMA 32.76 
52-W High 36.6 
52-W Low 19.56 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.72/-2.59
Enterprise Value
2.25B
Balance Sheet
Book Value Per Share
3.90
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.3842+0.1041+37.17%-- 
After Hours 0.37765 -0.00655 -1.70%
VTGNVistagen Therapeutics, Inc.0.3+0.055+22.45%-- 
After Hours 0.2926 -0.0074 -2.47%
RXRXRecursion Pharmaceuticals3.31+0.13+4.09%-- 
After Hours 3.32 +0.01 +0.30%
IBRXImmunityBio6.95-0.2-2.80%-- 
After Hours 6.9499 -0.0001 0.00%
GOSSGossamer Bio0.1815+0.0079+4.55%-- 
After Hours 0.1844 +0.0029 +1.60%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel smallmolecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.